DVT: a new era in anticoagulant therapy.
作者信息
Mackman Nigel, Becker Richard C
机构信息
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA.
出版信息
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):369-71. doi: 10.1161/ATVBAHA.110.203497. Epub 2010 Feb 5.
Abstract
摘要
相似文献
1
DVT: a new era in anticoagulant therapy.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):369-71. doi: 10.1161/ATVBAHA.110.203497. Epub 2010 Feb 5.
2
New oral anticoagulants.
CMAJ. 2013 Mar 5;185(4):E212. doi: 10.1503/cmaj.120078. Epub 2012 Nov 12.
3
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0.
4
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
J Thromb Haemost. 2009 Aug;7(8):1313-20. doi: 10.1111/j.1538-7836.2009.03503.x. Epub 2009 Jun 3.
5
Current state of anticoagulants to treat deep venous thrombosis.
Curr Cardiol Rep. 2014 Mar;16(3):463. doi: 10.1007/s11886-013-0463-2.
6
New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?
Pharmacoeconomics. 2009;27(10):793-5. doi: 10.2165/11313780-000000000-00000.
7
Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Am J Ther. 2011 Jul;18(4):332-8. doi: 10.1097/MJT.0b013e3181da0773.
8
[Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Farm Hosp. 2009 May-Jun;33(3):125-33.
9
[Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism].
Farm Hosp. 2009 May-Jun;33(3):123-4. doi: 10.1016/s1130-6343(09)71153-5.
10
New oral anticoagulants: should they replace heparins and warfarin?
Hellenic J Cardiol. 2011 Jan-Feb;52(1):52-67.
引用本文的文献
1
Management of Deep Vein Thrombosis in Emergency Departments;Time to Change the Viewpoint.
Emerg (Tehran). 2016 Winter;4(1):47.
2
Role of tissue factor in venous thrombosis.
Annu Rev Physiol. 2011;73:515-25. doi: 10.1146/annurev-physiol-042210-121137.
本文引用的文献
1
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29.
2
Current treatment of venous thromboembolism.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):372-5. doi: 10.1161/ATVBAHA.109.197145. Epub 2010 Feb 5.
3
Inhibition of factor XIa as a new approach to anticoagulation.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):388-92. doi: 10.1161/ATVBAHA.109.197178. Epub 2010 Feb 5.
4
Rivaroxaban: a new oral factor Xa inhibitor.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):376-81. doi: 10.1161/ATVBAHA.110.202978. Epub 2010 Feb 5.
5
Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):382-7. doi: 10.1161/ATVBAHA.110.203117. Epub 2010 Feb 5.
6
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.
Cell. 2009 Dec 11;139(6):1143-56. doi: 10.1016/j.cell.2009.11.001.
7
The new oral anticoagulants.
Blood. 2010 Jan 7;115(1):15-20. doi: 10.1182/blood-2009-09-241851. Epub 2009 Oct 30.
8
Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
9
New anticoagulants for treatment of venous thromboembolism.
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):380-6. doi: 10.1161/ATVBAHA.108.162677.
10
Triggers, targets and treatments for thrombosis.
Nature. 2008 Feb 21;451(7181):914-8. doi: 10.1038/nature06797.
Zotero 插件